Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,730.50
  • Today's Change2.00 / 0.12%
  • Shares traded712.29k
  • 1 Year change17.67%
  • Beta0.5565
Data delayed at least 20 minutes, as of May 03 2024 10:09 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year GSK plc had net income fall -67.05% from 14.96bn to 4.93bn despite a 3.42% increase in revenues from 29.32bn to 30.33bn. An increase in the selling, general and administrative costs as a percentage of sales from 27.72% to 29.77% was a component in the falling net income despite rising revenues.
Gross margin72.76%
Net profit margin15.48%
Operating margin20.02%
Return on assets8.13%
Return on equity34.95%
Return on investment12.25%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at GSK plc fell by 567.00m. However, the company earned 6.77bn from its operations for a Cash Flow Margin of 22.32%. In addition the company used 1.60bn on investing activities and also paid 5.64bn in financing cash flows.
Cash flow per share1.69
Price/Cash flow per share10.29
Book value per share3.34
Tangible book value per share-2.12
More ▼

Balance sheet in GBPView more

GSK plc has a Debt to Total Capital ratio of 57.33%, a lower figure than the previous year's 140.81%.
Current ratio0.8669
Quick ratio0.5796
Total debt/total equity1.28
Total debt/total capital0.5733
More ▼

Growth rates in GBP

Year on year, growth in dividends per share fell -5.31% while earnings per share excluding extraordinary items rose 15.03%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)4.74%
Div growth rate (5 year)-10.32%
Payout ratio (TTM)53.46%
EPS growth(5 years)6.39
EPS (TTM) vs
TTM 1 year ago		-0.9634
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.